05:48 AM EDT, 04/30/2024 (MT Newswires) -- SynOx Therapeutics said Tuesday it signed a loan facility of up to $35 million with Hercules Capital ( HTGC ) .

The company said the initial tranche was drawn on signing, and the subsequent three tranches are available over the medium term and upon achievement of certain clinical milestones.

It said the loan facility provides flexibility to fund additional clinical work in Tenosynovial Giant Cell Tumour treatments.

Additionally, the funding will support the registration and commercialization of emactuzumab in TGCT, and potentially explore the use of emactuzumab in other diseases, the company said.

Price: 19.32, Change: +0.10, Percent Change: +0.52